3D printing software developer Materialise has garnered U.S. Food and Drug Administration (FDA) clearance for its Mimics Enlight cardiovascular planning software.
Mimics Enlight enables users to produce 3D patient-specific models to help in planning transcatheter mitral valve replacement (TMVR) procedures, according to the vendor. Specifically, these 3D models can assist clinicians in taking measurements to screen patients for TMVR therapy, planning procedures, and determining the appropriate size and positioning of TMVR devices, Materialise said.
Materialise developed Mimics Enlight in collaboration with the Henry Ford Health System in Detroit.
